Get the Stockscreener App
8.81
3.45%
-0.315
Zevra Therapeutics Inc stock is traded at $8.81, with a volume of 453.11K.
It is down -3.45% in the last 24 hours and up +1.73% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$9.125
Open:
$9.03
24h Volume:
453.11K
Relative Volume:
0.83
Market Cap:
$507.43M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-6.8295
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-5.06%
1M Performance:
+1.73%
6M Performance:
+3.89%
1Y Performance:
+93.63%
1-Day Range:
$8.81
$9.21
1-Week Range:
$8.81
$9.62
52-Week Range:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.81 | 507.43M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra Therapeutics’ SWOT analysis: strong MIPLYFFA launch boosts stock outlook - Investing.com
Cantor Fitzgerald Forecasts ZVRA FY2026 Earnings - Defense World
Squarepoint Ops LLC Purchases 4,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
ZVRAForm DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material - mx.advfn.com
BNP Paribas Financial Markets Buys New Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
ProShare Advisors LLC Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 6,877 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Deutsche Bank AG - Defense World
Zevra Therapeutics confirms board members through stockholder vote By Investing.com - Investing.com South Africa
Zevra Announces Final Results of 2025 Annual Meeting of Stockhol - GuruFocus
Zevra Therapeutics Elects New Directors at Annual Meeting - TipRanks
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders - The Manila Times
Zevra Therapeutics confirms board members through stockholder vote - Investing.com
Zevra Stockholders Overwhelmingly Reject Opposition, Back Current Board with 74% Support - Stock Titan
D. E. Shaw & Co. Inc. Purchases Shares of 25,075 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trading (ZVRA) With Integrated Risk Controls - news.stocktradersdaily.com
Zevra Therapeutics’ SWOT analysis: rare disease focus drives stock potential By Investing.com - Investing.com Nigeria
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - Insider Monkey
Zevra Therapeutics’ SWOT analysis: rare disease focus drives stock potential - Investing.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Analysts - Defense World
Wall Street Zen Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Buy” - Defense World
Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Cashes in on First FDA-Approved NPC Treatment with PRV - Genetic Engineering and Biotechnology News
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26% - simplywall.st
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, - GlobeNewswire
Zevra Therapeutics ISS, Glass Lewis & Egan-Jones Recommend Zevra Stockholders Vote For Co's Director Nominees - marketscreener.com
ZVRA Receives Proxy Advisory Firms' Recommendations for Annual Meeting | ZVRA Stock News - GuruFocus
All Three Leading Proxy Advisory FirmsISS, Glass Lewis, and Egan-JonesRecommend Zevra Stockholders Vote FOR the Company's Director Nominees - The Manila Times
Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst - Defense World
Price T Rowe Associates Inc. MD Purchases 6,966 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Cantor Fitzgerald Brokers Boost Earnings Estimates for ZVRA - Defense World
What is William Blair’s Estimate for ZVRA Q1 Earnings? - Defense World
Zevra Therapeutics signals accelerated MIPLYFFA adoption and $148.3M capital infusion while expanding global reach - MSN
Q2 EPS Forecast for Zevra Therapeutics Lifted by Analyst - Defense World
Cantor Fitzgerald Reaffirms Overweight Rating for Zevra Therapeutics (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success - TipRanks
With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (ZVRA) Reports Strong Q1 Performance, Bolstered by Capital Infusion - GuruFocus
ZVRA Stock Update: Cantor Fitzgerald Reiterates Overweight Ratin - GuruFocus
Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views - Benzinga
ZVRA Stock Update: Cantor Fitzgerald Reiterates Overweight Rating | ZVRA Stock News - GuruFocus
Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On? - Benzinga
Zevra Therapeutics (ZVRA) Target Price Increased by Analyst | ZV - GuruFocus
Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance - TipRanks
Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP - TipRanks
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):